AMED TRAK, ENES SEYDA ŞAHİNER, ELİF UNAL, DİLARA BULUT GOKTEN, ESRA FIRAT OĞUZ, İHSAN ATEŞ
Ankara City Hospital Medical Journal - 2023;2(3):104-109
INTRODUCTION: We aimed to investigate the relationship between serum HMGB-1 levels and the clinical course of COVID-19 disease. METHODS: A total of 86 patients, 43 patients in each group, were included in the study. According to the Ministry of Health’s COVID-19 Diagnostic Guide, patients were divided into 2 groups as mild/moderate pneumonia and severe pneumonia. In addition to routine tests, blood samples were taken for serum HMGB-1 level analysis. At the time of blood draw, all patients were within the first 14 days of symptom onset. Results: HMGB-1 (High mobility group box protein 1) level of the patients in the mild Covid-19 pneumonia group was 4233.84 pg/ml, and the serum HMGB-1 level of the patients in the moderate-severe pneumonia group was 4804.35 pg/ml. There was no significant difference between the two groups (P=0.146). DISCUSSION AND CONCLUSION: We did not find a significant difference between the two groups in blood samples taken in the first 14 days from the onset of symptoms in COVID-19 patients.
